CD109 表达作为癌症患者预后生物标志物的效用：系统评价和荟萃分析。
Usefulness of CD109 expression as a prognostic biomarker in patients with cancer: A systematic review and meta-analysis.
机构信息
Department of Pathology, Gyeongsang National University Changwon Hospital, Changwon.
Department of Pathology, Soonchunhyang University College of Medicine.
出版信息
Medicine (Baltimore). 2021 Mar 19;100(11):e25006. doi: 10.1097/MD.0000000000025006.
BACKGROUND
It has been revealed that CD109 expression is associated with prognosis in cancer patients, but it remains unclear thus far. Therefore, we performed a meta-analysis in the present study for a better assessment of the prognostic role of CD109 expression in cancer patients.
METHODS
Eligible studies were collected through a search of the PubMed, Embase, Cochrane Library, and Scopus databases. The pooled hazard ratio (HR) with 95% confidence interval (CI) was evaluated to reveal the association between CD109 expression and overall survival (OS) in cancer patients.
RESULTS
Seven studies with 1583 patients were enrolled. The pooled HR with 95% CI was calculated as 2.31 (95% CI 1.93-2.76, P < .001), suggesting an association between high expression of CD109 and unfavorable OS in cancer patients.
CONCLUSION
This analysis indicated that CD109 expression could be used as a prognostic biomarker in cancer patients. This is the first meta-analysis to report the relationship between CD109 expression and prognosis in cancer patients.
背景
已经发现 CD109 的表达与癌症患者的预后相关，但目前尚不清楚。因此，我们在本研究中进行了荟萃分析，以更好地评估 CD109 表达在癌症患者中的预后作用。
方法
通过检索 PubMed、Embase、Cochrane 图书馆和 Scopus 数据库收集了符合条件的研究。评估合并风险比（HR）及其 95%置信区间（CI），以揭示 CD109 表达与癌症患者总体生存率（OS）之间的关联。
结果
纳入了 7 项包含 1583 名患者的研究。计算合并 HR 及其 95%CI 为 2.31（95%CI 1.93-2.76，P<0.001），表明 CD109 高表达与癌症患者的不良 OS 相关。
结论
这项分析表明 CD109 表达可以作为癌症患者的预后生物标志物。这是首次报道 CD109 表达与癌症患者预后之间关系的荟萃分析。
Zotero 插件